-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Outperform on Dianthus Therapeutics, Lowers Price Target to $50

Benzinga·05/13/2025 12:27:12
Listen to the news
Baird analyst Joel Beatty maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and lowers the price target from $58 to $50.